RTP Mobile Logo
Cancer Conference Update: A Multimedia Review of Key Breast Cancer Presentations from the 2016 San Antonio Breast Cancer Symposium and the 2017 American Society of Clinical Oncology Annual Meeting
Released October 2017

Featuring key slides from the most important breast cancer presentations of SABCS 2016 and ASCO 2017 and video interviews with Drs Kimberly L Blackwell, Karen A Gelmon, Ian E Krop, Kathy D Miller, Rita Nanda and Sara Tolaney. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

    OVERVIEW OF ACTIVITY
    Breast cancer remains the most frequently diagnosed cancer in women, and in 2017 in the United States alone the disease will culminate in an estimated 255,180 new cases and 41,070 deaths. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only about 5% of women have identifiable distant metastases with primary diagnosis. Consequently, the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.

    The current clinical management of breast cancer is multidisciplinary and includes surgical resection of local disease with or without radiation therapy and the treatment of systemic disease (micro- or macroscopic) with cytotoxic chemotherapy, endocrine therapy, biologic therapy or combinations of these approaches. The indication and/or utility of these available local and systemic treatment options is largely based on a number of prognostic and predictive risk factors present in the patient or the tumor at the time of diagnosis. In fact, as the field of oncology is challenged to improve the precision with which it therapeutically targets malignant cells, biomarker-driven treatment algorithms have become the “norm” for many tumor types, particularly breast cancer.

    Several consensus- and evidence-based treatment guidelines are available and aim to assist clinicians with making breast cancer management decisions in the face of this dynamic environment. But despite the existence of these tools, many areas of controversy persist within academic and community settings. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies in the management of breast cancer, which in turn facilitates optimal patient care.

    LEARNING OBJECTIVES

    • Appraise recently published clinical research data and adapt current breast cancer diagnostic and management approaches on the basis of practice-changing findings.
    • Appreciate the similarities and differences between existing genomic assays, and use this information to select the appropriate platform to assess risk and individualize therapy for patients with invasive and noninvasive early breast cancer.
    • Develop an evidence-based algorithm for the initial and long-term treatment of localized hormone receptor-positive pre- and postmenopausal breast cancer.
    • Individualize the selection of evidence-based neoadjuvant and adjuvant chemobiologic regimens for patients with HER2-positive breast cancer.
    • Develop an understanding of the mechanisms of action, available research data and ongoing trials of approved and investigational CDK4/6 inhibitors and other novel therapies under investigation in the management of advanced breast cancer.
    • Consider clinical data and patient preferences in the selection and sequencing of available therapeutic agents for patients with newly diagnosed and metastatic triple-negative breast cancer.
    • Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials investigating novel therapeutic agents and strategies.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for continuing medical education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of slide and video components. To receive credit, the participant should review the slide presentations, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/CACUBreast17/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Kimberly L Blackwell, MD
    Professor of Medicine
    Director, Breast Cancer Program
    Duke Cancer Institute
    Durham, North Carolina

    Advisory Committee: Advaxis Inc, Bayer HealthCare Pharmaceuticals, Eisai Inc, MacroGenics Inc, Merck, Novartis, Pfizer Inc, Pierian Biosciences, Syndax Pharmaceuticals Inc; Consulting Agreements: Celgene Corporation, Coherus Biosciences, G1 Therapeutics, Genentech BioOncology, Lilly, Puma Biotechnology Inc, Sandoz, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Celgene Corporation, Genentech BioOncology, Novartis, Pfizer Inc.

    Karen A Gelmon, MD
    Professor, Medicine
    Head, Division of Medical Oncology
    University of British Columbia
    Medical Oncologist, BC Cancer Agency
    Vancouver Cancer Centre
    Vancouver, Canada

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Lilly, Merck, Novartis, Pfizer Inc.

    Ian E Krop, MD, PhD
    Director of Clinical Research
    Breast Oncology Center
    Dana-Farber Cancer Institute
    Assistant Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Genentech BioOncology, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Roche Laboratories Inc.

    Kathy D Miller, MD
    Co-Director, IU Simon Cancer Center Breast Cancer Program
    Ballvé-Lantero Scholar in Oncology
    Professor of Medicine
    Division of Hematology/Oncology
    Indiana University Melvin and Bren Simon Cancer Center 
    Indianapolis, Indiana

    Contracted Research: Astellas Pharma Global Development Inc, Genentech BioOncology, Medivation Inc, a Pfizer Company, Merrimack Pharmaceuticals Inc, Novartis, Pfizer Inc, Taiho Oncology Inc; Data Monitoring Committee: ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Merck.

    Rita Nanda, MD
    Co-Director, Breast Medical Oncology
    Associate Professor of Medicine
    Section of Hematology/Oncology
    The University of Chicago
    Chicago, Illinois

    Advisory Committee: Celgene Corporation, Pfizer Inc, Puma Biotechnology Inc, Syndax Pharmaceuticals Inc; Contracted Research:Celgene Corporation, Genentech BioOncology, Merck.

    Sara Tolaney, MD, MPH
    Department of Medical Oncology
    Dana-Farber Cancer Institute
    Assistant Professor in Medicine
    Harvard Medical School
    Boston, Massachusetts 

    Contracted Research: Genentech BioOncology, Lilly, Merck, Novartis, Pfizer Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Foundation Medicine, Lilly and Novartis.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2017
    Expiration date: October 2018

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Genomic assays and clinical decision-making for patients with breast cancer (BC)

Management of early BC in the adjuvant setting

Potential role of PARP inhibitors in metastatic BC (mBC)

CDK4/6, mTOR and PI3K inhibitors for ER-positive, HER2-negative BC

Management of HER2-positive BC

Novel agents under investigation for triple-negative BC (TNBC)

Select Publications